# KingSung Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kingsung-medical

- Industry: Medical Devices & Equipment
- Headquarters: Tianjin, China
- Website: www.kingsungmedical.com/
- Latest round: Series A (Jun 2, 2026)
- Investors on record: 1

## About

Based in Tianjin, China, KingSung Medical specializes in advanced biotechnology solutions, focusing on healthcare innovations aimed at improving treatment outcomes and optimizing medical processes for patients and providers.KingSung Medical, established in 2008 in Tianjin, China, operates in the biotechnology sector, providing biopharmaceuticals and diagnostic tools. The company has not undergone significant operational changes and does not have known subsidiaries or parent companies. There has been one funding deal recorded, with the most recent occurring on June 2, 2026, where KingSung Medical was the investment target.KingSung Medical focuses on advanced biotechnology solutions, primarily in healthcare innovations. It offers a range of biopharmaceuticals and diagnostic tools aimed at enhancing patient treatment outcomes and streamlining medical processes. The firm serves hospitals, healthcare providers, and research institutions predominantly in the Asia-Pacific region, including markets such as China, Japan, and South Korea, and consistently expands its product line to meet sector demands.Revenue for KingSung Medical is generated primarily through B2B transactions with healthcare institutions and research organizations. The company engages in direct sales of its products under partnership agreements, typically involving bulk orders or long-term supply contracts. Pricing varies based on order volume and product categories, facilitating a consistent revenue flow to support ongoing product development.In June 2026, KingSung Medical raised over CNY 100 million in Series A funding led by Proxima Ventures. The company will utilize this funding to enhance research and development in cutting-edge technology, strengthen collaborations across industry, academia, and research, and expedite expansion into overseas markets. These strategic initiatives aim to contribute to the high-quality development of the medical industry.

## Funding rounds

- Series A, Jun 2, 2026 — Proxima Capital

## Investors

- Proxima Capital (https://capitalatlas.ai/funds/proxima-capital) — Series A